MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • White Papers
  • DeviceTalks

Novartis unit Alcon picks up Tear Film Innovations

December 20, 2018 By Brad Perriello Leave a Comment

Novartis (NYSE:NVS) subsidiary Alcon said it acquired Tear Film Innovations for an undisclosed amount. San Diego-based TFI makes the iLux system, which is designed to treat blocked meibomian glands in eyelids. The company had raised a total of $18 million in two rounds in as many years, split evenly between the two. iLux won 510(k) clearance from the FDA […]

Filed Under: Featured, Mergers & Acquisitions, Optical/Ophthalmic, Wall Street Beat Tagged With: Alcon, Novartis, tearfilminnovations

Google’s Verily spikes glucose-sensing lens project with Novartis’ Alcon

November 19, 2018 By Fink Densford Leave a Comment

Google (NSDQ:GOOG) life sciences company Verily said late last week that it is putting its joint project with Novartis (NYSE:NVS) unit Alcon to develop a glucose-sensing contact lens on hold due to difficulties in obtaining reliable tear glucose readings. The project, which began in 2014, aimed to develop a contact lens that could measure glucose levels for individuals living […]

Filed Under: Business/Financial News, Diabetes, Optical/Ophthalmic, Research & Development Tagged With: Alcon, google, Novartis, Verily

FDA updates warning on Alcon’s CyPass glaucoma stents

October 25, 2018 By Fink Densford Leave a Comment

The FDA today released an update to a warning on Novartis (NYSE:NVS) subsidiary Alcon’s CyPass glaucoma stents, saying that clinicians should still refrain from using the stents and should monitor patients who’ve received them for endothelial cell density loss. In August, Alcon voluntarily pulled the stents from the global market based on an analysis of five-year post-surgery […]

Filed Under: Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Stents Tagged With: Alcon, Novartis

The 20 largest medical device companies in the world

September 18, 2018 By Chris Newmarker Leave a Comment

The medical device industry saw even more consolidation over the past year, as evidenced by Medical Design & Outsourcing‘s newest Big 100 list. It used to be that a company had to have at least $100 million in annual revenue to make it on the list. This time around, No. 100 on the list is […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: 3m, Abbott, Alcon, B. Braun, Baxter, BD, bectondickinson, Boston Scientific, Essilor, Novartis, Owens & Minor, Zimmer Biomet

Alcon withdraws all CyPass micro-stents, says it will not affect spin-off

August 31, 2018 By Fink Densford Leave a Comment

Novartis (NYSE:NVS)’s Alcon said this week it is voluntarily withdrawing its CyPass micro-stents from the global market, but that the withdrawal will not affect its planned spin-out. The decision to pull the devices comes off the analysis of five-year post-surgery data from the Compass-XT study of the device, which showed that patients treated with the stent had […]

Filed Under: Business/Financial News, Optical/Ophthalmic Tagged With: Alcon, Novartis

Novartis to spin out Alcon ophthalmic subsidiary

June 29, 2018 By Brad Perriello Leave a Comment

Novartis (NYSE:NVS) said today that it’s planning to spin its Alcon ophthalmology subsidiary into a publicly traded company after years of speculation that it wanted to sell the ill-starred division. The Swiss pharma giant said it intends to hold on to Alcon’s $4.6 billion ophthalmic pharmaceuticals business under the Novartis Innovative Medicines umbrella, continuing a […]

Filed Under: Mergers & Acquisitions, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Alcon, Novartis

Alcon launches project to reduce cataract blindness

May 8, 2018 By Danielle Kirsh Leave a Comment

Alcon, a division of Novartis, launched its Alcon Cares Project 100 to take steps in reducing cataract blindness globally. The company also plans to donate 100 reprocessed Infiniti units to eligible clinics in Asia, Central and South America and Africa over the next three years. Alcon aims to reduce cataract blindness by providing equipment to […]

Filed Under: Hospital Care, Surgical Tagged With: Alcon, cataracts

InVivo Therapeutics lifts Toselli to permanent prez, CEO | Personnel Moves February 6, 2018

February 6, 2018 By Fink Densford Leave a Comment

InVivo Therapeutics (NSDQ:NVIV) said yesterday it made Dr. Richard Toselli’s spot in the corner office permanent, lifting him from acting CEO to prez and CEO. Dr. Toselli will maintain his position on the company’s board and as its chief medical officer, the position he was given when he joined the company last July. Prior to joining InVivo, […]

Filed Under: Business/Financial News Tagged With: Alcon, Baxter, Boston Scientific, Faxitron, GE Healthcare, InVivo Therapeutics, johnsonandjohnson, Lima Corporate, Luxottica, Medizone, Medtronic, performancehealth, Respicardia, Robocath, Sanofi-Aventis, T2 Biosystems Inc.

7 medtech stories we missed this week: Oct. 13, 2017

October 13, 2017 By Danielle Kirsh Leave a Comment

From Orthocell’s distribution deal to CorNeat unveiling its artificial cornea, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. OrthoCell inks Australian distro deal Orthocell announced in an Oct. 10 press release that it has signed a distribution deal with Surgical Specialities. The deal will make Surgical Specialities the […]

Filed Under: 510(k), Business/Financial News, Clinical Trials, Cosmetic/Aesthetic, Food & Drug Administration (FDA), Implants, Patient Monitoring, Regulatory/Compliance, Research & Development Tagged With: Alcon, Bonesupport, CorNeat, Faxitron, Masimo, MedTech, Orthocell, Viveve Medical

The 20 largest medical device companies in the world

September 19, 2017 By Chris Newmarker Leave a Comment

When it comes to the largest medical device companies, it’s a changing cast of players – as demonstrated once again in Medical Design & Outsourcing’s latest Big 100 list. We pulled financial regulatory filings and reached out to major companies in some cases to create a list of the 100 largest medical device companies in […]

Filed Under: Big Data, Business/Financial News Tagged With: 3m, Abbott, Alcon, B. Braun, Big 100, Novartis, Olympus, Zimmer Biomet

Novartis unit Alcon posts modest Q2 gain

July 18, 2017 By Brad Perriello Leave a Comment

(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today. The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued […]

Filed Under: MassDevice Earnings Roundup, Mergers & Acquisitions, Optical/Ophthalmic, Wall Street Beat Tagged With: Alcon, Novartis

  • 1
  • 2
  • 3
  • 4
  • Next Page »
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS